A double whammy of excellent information despatched
Pfizer
shares increased early Tuesday, respiratory life right into a inventory that had fallen 21% to this point this yr as of the shut of buying and selling on Monday.
Not solely had been earnings increased than Wall Road anticipated,
Pfizer
(ticker: PFE) introduced sturdy new information on its maternal respiratory syncytial virus program. The corporate stated it expects to submit the shot for Meals and Drug Administration approval by the top of the yr.
